Financial Gravity Asset Management, Inc. Neurocrine Biosciences Inc Transaction History

Financial Gravity Asset Management, Inc.

  • $400 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$130.4 - $143.74 $0 - $0
0 New
0 $40,000
Q1 2023

May 12, 2023
BUY
$94.11 - $123.02 $9,505 - $12,425
101 New
101 $2.06 Million
Q3 2019

Oct 15, 2019
SELL
$83.82 - $101.5 $251 - $304
-3 Closed
0 $0
Q2 2019

Jul 26, 2019
BUY
$72.24 - $91.27 $216 - $273
3 New
3 $0

Others Institutions Holding NBIX

# of Institutions
656
Shares Held
96.6M
Call Options Held
282K
Put Options Held
281K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $10.7B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Financial Gravity Asset Management, Inc. Portfolio

Follow Financial Gravity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email